Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Active
Last updated: November 12, 2025
Non-Hormonal Intravaginal Contraceptive
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal - Other
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Dare BioScience Inc.
Active
Last updated: November 12, 2025
Xulane Lo

Low-Dose Weekly Dermal Patch

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Transdermal
  • Intended Duration: Short-Acting
  • Development Stage: Phase III
  • Developer(s)/Researcher(s): Viatris
Active
Last updated: November 12, 2025
MoSAIC Platform

Monolithic Shape-Shifting Absorbable Implants for Chronic Care

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Long-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Brigham and Women's Hospital, MIT
Active
Last updated: November 12, 2025
FemBloc Permanent Contraceptive System
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Fallopian Tube
  • Intended Duration: Permanent
  • Development Stage: Phase III
  • Developer(s)/Researcher(s): Femasys Inc
Active
Last updated: November 12, 2025
Yaso Gel

PPCM Vaginal Gel

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Yaso Therapeutics, NIAID, Albert Einstein College of Medicine, University of Illinois at Chicago
Active
Last updated: August 6, 2025
6 Month Injectable Contraceptive
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Short-Acting
  • Development Stage: Phase III
  • Developer(s)/Researcher(s): FHI 360
Inactive
Last updated: July 30, 2025
Recombinant Anti-Mullerian Hormone
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Undetermined
  • Intended Duration: Undetermined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Oviva Therapeutics, Massachussetts General Hospital
Inactive
Last updated: June 24, 2025
UPA IUS

Ulipristal Acetate (UPA) Intrauterine System (IUS)

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Intrauterine
  • Intended Duration: Long-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): HRA Pharma, Population Council
Inactive
Last updated: June 20, 2025
Acyline

GnRH II Receptor Antagonists

  • User: Male
  • Hormonal: Hormonal
  • Delivery Type: Undetermined
  • Intended Duration: Undetermined
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): University of Washington, Monash University, Charles R. Drew University
Inactive
Last updated: May 30, 2025
PCL Microspheres Encapsulating LNG + EE
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Undetermined
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Vel's College of Pharmacy, University of Connecticut